News Archive
BioForce’s (BFNH) Nano eNabler™ System Makes Contributions to Stem Cell Research and Biosensor Development
BioForce’s (BFNH) Nano eNabler™ System Makes Contributions to Stem Cell Research and Biosensor Development
UAlbany NanoCollege Scientists Find Applications in NanoBiotechnology
ALBANY, NY, May 21, 2009 -- BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH) announced today that the results of innovative nanobioscience research conducted by the College of Nanoscale Science and Engineering (CNSE) of the University at Albany using the company’s Nano eNabler molecular printing system have been published in the journal Applied Surface Science.
The scholarly paper authored by CNSE Assistant Professor of Nanobioscience Dr. Nathaniel Cady and his collaborators from CNSE and the New York State Department of Health’s Wadsworth Center revealed his group’s progress toward creating miniaturized biosensors. Their development of a means of attaching DNA probes onto the surface of the material aluminum gallium nitride (AlGaN) could lead to new DNA biosensors with high sensitivity and commercially viable fabrication processes.
Additional projects in Dr. Cady’s lab are demonstrating that the Nano eNabler can also be used to directly dispense individual cells which are encapsulated with a protective coating. Dr. Cady is using the Nano eNabler to study the effects of local microenvironments on stem cells. By combining various physical structures with protein micropatterns, these researchers are able to examine the differentiation and proliferation of single stem cells in response to a precisely constructed biomimetic environment.
Kerry Frey, BioForce’s CEO, said, “With the world’s most advanced intellectual and technological infrastructure supporting nanotechnology education, research and development, the UAlbany NanoCollege is well positioned to make ultra-miniaturized biosensor technologies a reality with the help of BFNH’s Nano eNabler. Given the significant benefits the Nano eNabler’s capabilities provide in biological research to create minimally invasive diagnostic tests and devices with enhanced sensitivity, speed and flexibility, it is our expectation that breakthroughs like this will help drive customer demand to record levels during 2009.”
Dr. Robert Geer, Vice President for Academic Affairs and Chief Academic Officer of CNSE, said, “The partnership between the UAlbany NanoCollege and BioForce Nanosciences, a recognized leader in integrating cutting-edge nanoscale technologies to foster innovations in the critical area of life sciences, is already paying dividends. CNSE’s growing focus on educational and research initiatives in the field of nanobioscience, including this work led by Professor Nathaniel Cady, promises to enable exciting advances in disease diagnosis, treatment and prevention, helping to address one of the critical issues facing society in the 21st century.”
The rapidly growing field of bio-nanotechnology, at the intersection of biotechnology and nanotechnology, is an area of great interest to researchers. The ability to create environments containing ultra-micro to nanoscale features is critical in order to fully understand these interactions. Such interactions are keys to the development of novel and potentially blockbuster therapeutic agents because they are frequently the basis for critical cellular functions including tissue growth, organ generation and regeneration, and cancer cell metastasis. The Nano eNabler system is able to create these environments with ultra-miniaturized features through its proprietary ultra-micro to nanoscale fluid deposition technology.
#####
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences produces products and solutions for academic and industrial customers based upon its ultra-micro to nano scale fluid deposition platform. BioForce’s flagship product, the Nano eNabler™ molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; patterning and cell adhesion; and the printing of proteins to direct stem cell differentiation. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
About CNSE
The UAlbany CNSE is the first college in the world dedicated to education, research, development, and deployment in the emerging disciplines of nanoscience, nanoengineering, nanobioscience, and nanoeconomics. CNSE’s Albany NanoTech Complex is the most advanced research enterprise of its kind at any university in the world: a $4.5 billion, 800,000-square-foot complex that attracts corporate partners from around the world and offers students a one-of-a-kind academic experience. The UAlbany NanoCollege houses the only fully-integrated, 300mm wafer, computer chip pilot prototyping and demonstration line within 80,000 square feet of Class 1 capable cleanrooms. More than 2,200 scientists, researchers, engineers, students, and faculty work on site at CNSE’s Albany NanoTech, from companies including IBM, AMD, GLOBALFOUNDRIES, SEMATECH, Toshiba, ASML, Applied Materials, Tokyo Electron, Vistec Lithography and Atotech. For more information, visit http://www.cnse.albany.edu/.
Contacts:
Company Contact
Gregory D. Brown
Chief Financial Officer
515-233-8333 ext# 118
Investor Relations
Yes International
Rich Kaiser
800-631-8127
CNSE Contact:
Steve Janack
VP, Marketing & Communications
518-956-7322
